KRAS G12C inhibitor JMKX001899

{
  "id": "MLC-T-ONC-014660",
  "term": "KRAS G12C inhibitor JMKX001899",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable inhibitor of the oncogenic KRAS substitution mutation G12C, with potential antineoplastic activity. Upon oral administration, KRAS G12C inhibitor JMKX001899 targets and irreversibly binds to the KRAS G12C mutant, and locks it in an inactive state. This inhibits the activity of the KRAS G12C mutant, thereby preventing KRAS G12C mutant-mediated signaling. KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis. JMKX001899 is able to penetrate through the blood-brain barrier (BBB).",
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/kras-g12c-inhibitor-jmkx001899/"
}